天士力：TSL2109胶囊用于晚期实体瘤获批临床试验

Core Viewpoint - Tianshili's subsidiary, Jiangsu Diyi, has received approval from the National Medical Products Administration for clinical trials of TSL2109 capsules for advanced solid tumors [1] Company Summary - Tianshili's full subsidiary Jiangsu Diyi has been granted a clinical trial approval notice for TSL2109 capsules [1]